NXT007 vs Emicizumab for Hemophilia A

(ZEBRHA 2 Trial)

This trial tests two treatments, NXT007 (an experimental treatment) and emicizumab (a medication), to determine which is more effective and safer for people with hemophilia A. Hemophilia A is a condition where blood doesn't clot properly, causing frequent bleeding episodes. The study targets individuals with severe or moderate hemophilia A or any severity with certain inhibitors that hinder clotting factor activity. Participants will either continue their current treatment or switch to a new one to help prevent bleeding. Those with hemophilia A experiencing regular bleeding issues might find this trial suitable. As a Phase 3 trial, it represents the final step before FDA approval, offering access to potentially groundbreaking treatment.

The trial does not specify if you need to stop taking your current medications, but you cannot use systemic immunomodulators (medications that affect the immune system) during the study, except for antiretroviral therapy for HIV.

Research has shown that NXT007, a new treatment for hemophilia A, has been well tolerated in studies. Previous research found it generally safe at different doses, with no major safety concerns reported, such as blood clots.

Emicizumab, the treatment to which NXT007 is being compared, has a well-established safety record. The FDA has already approved it for people with hemophilia A, indicating it has passed safety tests for this condition.

Unlike the standard treatment for Hemophilia A, which often involves regular injections of clotting factor replacements, NXT007 works by mimicking the action of a natural protein that helps blood clot. This new mechanism could offer more consistent protection against bleeding episodes. Researchers are excited about NXT007 because it may reduce the frequency of treatments compared to traditional approaches, promising a simpler and potentially more effective management of the condition.

This trial will compare NXT007 with Emicizumab for treating hemophilia A. Research has shown that NXT007 could be beneficial for this condition. Early results suggest it might help control bleeding, even in patients with factor VIII inhibitors. NXT007 is designed to mimic factor VIII, which is either absent or malfunctioning in people with hemophilia A. Initial studies found that NXT007 is generally well tolerated and may significantly reduce bleeding. Emicizumab, which participants in this trial may also receive, is already known to be effective and well tolerated for hemophilia A across different patient groups. These findings suggest that both treatments could effectively manage hemophilia A.¹⁶⁷⁸⁹